Equity Analysis /
Thailand

TH : Mega Lifesciences - Consumer health products continue to thrive

    CGS-CIMB
    18 January 2021
    Published byCGS-CIMB

    We expect Mega to post a solid 4Q20 core net profit of THB443m (+8.3% yoy, +15.5% yoy), driven by strong performance in its branded business. Myanmar and Thailand markets should be key revenue drivers in FY21F but Africa and Indonesia could provide Mega with long-term growth catalysts. Reiterate Add on Mega with a higher target price of THB47.